MRI software developer Bot Image has secured an expanded clearance from the U.S. Food and Drug Administration (FDA) clearance for its ProstatID AI software.
The firm had received its initial FDA clearance in 2022 for the use of ProstatID in detection and diagnosis of prostate cancer on MRI. With the new additional clearance, ProstatID can also be used in prostate cancer screening on MRI and biparametric MRI, according to the vendor.
